TBG Diagnostics (TDL)
TBG Diagnostics Ltd. is a global molecular diagnostics company, which engages in the development, manufacturing and marketing of molecular diagnostics kits, instruments and services primarily for the treatment of cancer. The company's focus is on development of the anti-angiogenesis and anti-metastatic oncology products. TBG Diagnostics was founded on September 26, 1989 and is headquartered in Melbourne, Australia.
|Market Price at 12-12-2017||$0.06|
|Price to Earnings Ratio||-4.98|
|Market Capitalisation||$13.06 (million)|
|Return on Equity (ROE)||-32.13%|